Statistik Asas
| CIK | 1756594 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Inventiva S.A. - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| July 29, 2025 |
Inventiva Reports Preliminary 2025 First-Half Financial Information1 EXHIBIT 99.1 Inventiva Reports Preliminary 2025 First-Half Financial Information1 Cash and cash equivalents at €122.1 million and €24.6 million in short-term deposits2 as of June 30, 2025 Revenues of €4.5 million recorded in H1 2025 Daix (France), New York City (New York, United States), July 29, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage bio |
|
| July 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, and |
|
| July 9, 2025 |
EXHIBIT 99.1 Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance Jason Campagna, MD, PhD, joins Inventiva as President of R&D and Chief Medical Officer, succeeding Pierre Broqua, PhD, and Michael Cooreman, MD Martine Zimmermann, PharmD, joins as Executive Vice President of Regula |
|
| July 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, and |
|
| July 7, 2025 |
Inventiva receives $10 million milestone payment from CTTQ EdgarFiling EXHIBIT 99.1 Inventiva receives $10 million milestone payment from CTTQ Daix (France), New York City (New York, United States), July 7, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), to |
|
| July 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, and |
|
| May 23, 2025 |
Inventiva reports 2025 First Quarter Financial Informationˆ EdgarFiling EXHIBIT 99.1 Inventiva reports 2025 First Quarter Financial Informationˆ Cash and cash equivalents at €67.9 million Daix (France), New York City (New York, United States), May 23, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated |
|
| May 23, 2025 |
Results of the Votes of the Combined Shareholders’ General Meeting of May 22, 2025 EXHIBIT 99.1 Results of the Votes of the Combined Shareholders’ General Meeting of May 22, 2025 Daix (France), New York City (New York, United States), May 23, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, and t |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, and t |
|
| May 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, and t |
|
| May 22, 2025 |
Description of the Share Repurchase Program Covered by the Liquidity Agreement with Kepler Chevreux EdgarFiling EXHIBIT 99.1 Description of the Share Repurchase Program Covered by the Liquidity Agreement with Kepler Chevreux Daix, May 22, 2025 Pursuant to Article 241-2 of the AMF General Regulations (Règlement Général de l’Autorité des marchés financiers), the purpose of this description is to present the objectives and terms of the Company’s share repurchase program approved by the Ordinary Gen |
|
| May 5, 2025 |
Subscription Agreement for [ABSAs]/[PFW-BSAs] Exhibit 99.1 Subscription Agreement for [ABSAs]/[PFW-BSAs] INVENTIVA S.A. 50, rue de Dijon 21121 Daix France The undersigned, [·] [acting in the name and on behalf of the investment funds it represents or advises listed hereafter] (the “Subscriber”) hereby confirms its agreement with you as follows: 1. This Subscription Agreement (including the annexes attached hereto, the “Agreement”) is made as |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2025 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant’s name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address of principal executive off |
|
| May 5, 2025 |
Inventiva secures the €116 million second tranche of its structured financing of up to €348 million Exhibit 99.2 PRESS RELEASE Inventiva secures the €116 million second tranche of its structured financing of up to €348 million ► Financing follows completion of enrollment of Phase 3 NATiV3 study evaluating lanifibranor in MASH and satisfaction of other specified conditions. Daix (France), New York City (New York, United States), May 5, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva |
|
| May 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2025 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant’s name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address of principal executive off |
|
| May 2, 2025 |
Exhibit 99.1 Translation for information purpose only INVENTIVA Société Anonyme with a Board of Directors with a share capital of EUR 956,623.91 Registered Office: 50, Rue de Dijon, 21121 Daix 537 530 255 Trade and Companies Register of Dijon Notice of meeting The shareholders of INVENTIVA (the “Company”) are informed that the ordinary and extraordinary general meeting (the “General Meeting”) will |
|
| April 30, 2025 |
EXHIBIT 99.1 Statement of total voting rights and shares forming the company’s share capital as of April 11, 2025 Article R. 22-10-23 of the French Commercial Code Market: Euronext Paris ISIN code / Mnemo: FR0013233012 / IVA Web site: www.inventivapharma.com Date Number of shares outstanding Total voting rights, gross (1) Total voting rights, net (2) April 11, 2025 95,662,391 108,635,435 108,574,8 |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, and |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, and |
|
| April 30, 2025 |
Combined General Meeting of May 22, 2025 - Availability of the preparatory documents EXHIBIT 99.1 Combined General Meeting of May 22, 2025 - Availability of the preparatory documents Daix (France), New York City (New York, United States), April 30, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), al |
|
| April 24, 2025 |
Exhibit 99.2 INVENTIVA S.A. Ordinary and Extraordinary General Meeting of Inventiva S.A. to be held on May 22, 2025 Instructions for beneficial owners of American Depositary Shares (“ADSs”) Beneficial owners of ADSs who wish to submit their votes in connection with the General Meeting of Inventiva to be held on May 22, 2025 should consult the voting instruction form delivered to them by The Bank o |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2025 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant’s name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address of principal executive o |
|
| April 24, 2025 |
Exhibit 99.1 Copyright © 2025 BetaNXT, Inc. or its affiliates. All Rights Reserved styleIPC Instructions to The Bank of New York, as Depositary (Must be received prior to 12:00 PM Eastern Time May 15, 2025) The undersigned Holder of American Depositary Receipts (“Receipts”) of Inventiva S.A. (the “Company”) hereby requests and instructs The Bank of New York, as Depositary, to vote or cause to be v |
|
| April 15, 2025 |
Exhibit 4.3 Summary of Free Share Plans Free Shares (actions gratuites) are allotted for free to holders at an issuance price equal to the par value as set forth in the by-laws (€0.01). The issuance of the Free Shares will occur automatically at the end of the vesting period, by way of a capital increase, which will be realized by debiting the unavailable reserve (réserve non disponible) establish |
|
| April 15, 2025 |
DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Exhibit 2.4 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description sets forth certain material terms and provisions of the securities of Inventiva S.A. (“Inventiva,” the “Company,” “we,” “us” and “our”) that are registered under Section 12 of the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”). This descrip |
|
| April 15, 2025 |
Exhibit 13.1 Certification by the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 |
|
| April 15, 2025 |
CODE OF MARKET CONDUCT Up to date as of April 18, 2017 Exhibit 11.1 CODE OF MARKET CONDUCT Up to date as of April 18, 2017 Translation for information purposes only TABLE OF CONTENT INTRODUCTION 3 DEFINITIONS 4 1. CONCEPT OF INSIDE INFORMATION 7 2. HANDLING OF INSIDE INFORMATION 7 2.1 Principle of financial disclosure 7 2.2 Insider List Registration 8 3. RULES APPLICABLE TO ANY PERMANENT AND OCCASIONAL INSIDER 9 3.1 General duty of confidentiality 9 3 |
|
| April 15, 2025 |
Exhibit 1.1 INVENTIVA Société anonyme à Conseil d’administration with a share capital of €956,623.91 Registered office: 50 Rue de Dijon, 21121, Daix, France Dijon Trade and Companies Register 537 530 255 ARTICLES OF ASSOCIATION UPDATED TO REFLECT THE CHIEF EXECUTIVE OFFICER’S DECISIONS OF 19th December 2024 PART I FORM - NAME - OBJECTS - REGISTERED OFFICE - TERM ARTICLE 1. FORM The company (the “C |
|
| April 15, 2025 |
Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rule 13a-14(a) or Rule 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Jean Volatier, certify that: 1. I have reviewed this annual report on Form 20-F of Inventiva S.A.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF |
|
| April 15, 2025 |
Exhibit 4.4 Summary of Stock-Option Plans On December 20, 2024, the Company’s board of directors (the “Board”) granted 12,898,116 stock-options (the “SO 2024-1”) at a price of two euros and thirty-five cents (EUR 2.35) per SO 2024-1, to Mark Pruzanski, the Chairman of the Board of the Company. The SO 2024-1 will vest (but, for the avoidance of doubt, will not become exercisable) on the basis of th |
|
| April 15, 2025 |
Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rule 13a-14(a) or Rule 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Frédéric Cren, certify that: 1. I have reviewed this annual report on Form 20-F of Inventiva S.A.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or |
|
| April 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2025 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant’s name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address of principal executive o |
|
| April 11, 2025 |
Exhibit 99.1 Translation for information purpose only INVENTIVA Société Anonyme with a Board of Directors With a share capital of EUR 956,623.91 Registered Office: 50, Rue de Dijon, 21121 Daix 537 530 255 Trade and Companies Register of Dijon Notice of meeting to the Ordinary and Extraordinary General Meeting dated May 22, 2025 The shareholders of INVENTIVA (the “Company”) are informed that the or |
|
| April 1, 2025 |
EXHIBIT 99.1 Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis Target enrollment exceeded with 1009 patients randomized in the main cohort and 410 patients in the exploratory cohort Topline results from NATiV3 projected in the second half of 2026 and, if positive, expected to be the basis for submission for |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, and |
|
| March 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, and |
|
| March 26, 2025 |
Inventiva reports its 2024 full year results and provides a business update EXHIBIT 99.1 Inventiva reports its 2024 full year results and provides a business update Revenues of €9.2 million for the full year of 2024 Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million Structured Financing closed with aggregate gross proceeds of €116 million Last patient screened in the NATiV3 Phase 3 clinical trial of lanifibranor in MASH |
|
| February 20, 2025 |
EXHIBIT 99.1 Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial Initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 study Positive results could support the initiation of a pivotal Phase 3 trial in pat |
|
| February 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, |
|
| February 14, 2025 |
EX-99.1 2 tm256094d1ex-1.htm EXHIBIT 1 Exhibit 1 Joint Filing Agreement In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the ordinary shares of Inventiva S.A. and further agree that this agreement be included as an |
|
| February 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, |
|
| February 10, 2025 |
Inventiva reports preliminary 2024 fiscal year financial resultsˆ and provides a business update EXHIBIT 99.1 Inventiva reports preliminary 2024 fiscal year financial resultsˆ and provides a business update Revenues of €9.2 million for the full year of 2024 Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million structured financing closed with aggregate gross proceeds of €116 million Last patient screened in the NATiV3 Phase 3 clinical trial of |
|
| December 16, 2024 |
Exhibit 99.2 PRESS RELEASE Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million ► Inventiva secures €21.4 million leading to completion of the first tranche of the financing for c. €116 million, part of the multi-tranche equity financing of up to €348 million announced on October 14, 2024. ► Proceeds from the comp |
|
| December 16, 2024 |
Subscription Agreement for T1 bis [Shares] [Pre-Funded Warrants] Exhibit 99.1 Subscription Agreement for T1 bis [Shares] [Pre-Funded Warrants] INVENTIVA S.A. 50, rue de Dijon 21121 Daix France Inventiva S.A., a société anonyme organized under the laws of the French Republic, with a share capital of €870,776.95, consisting of 87,077,695 ordinary shares of €0.01 nominal value each (the “Ordinary Shares” and each, an “Ordinary Share”), and registered with the Comm |
|
| December 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2024 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant’s name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address of principal executiv |
|
| December 12, 2024 |
Results of the votes of the Combined Shareholders’ General Meeting of December 11, 2024 EXHIBIT 99.1 Results of the votes of the Combined Shareholders’ General Meeting of December 11, 2024 Daix (France), New York City (New York, United States), December 11, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steato |
|
| December 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, |
|
| November 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2024 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant’s name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address of principal executiv |
|
| November 26, 2024 |
Exhibit 99.1 Translation for information purpose only INVENTIVA French société Anonyme with a Board of Directors with a share capital of EUR 870,776.95 Registered Office: 50, Rue de Dijon, 21121 Daix 537 530 255 Trade and Companies Register of Dijon Notice of the combined general meeting of December 11, 2024 The shareholders of INVENTIVA are informed that the Ordinary and Extraordinary General Mee |
|
| November 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, |
|
| November 21, 2024 |
Inventiva reports 2024 Third Quarter Financial Information1 EXHIBIT 99.1 Inventiva reports 2024 Third Quarter Financial Information1 Cash and cash equivalents at €13.9 million, as of September 30, 2024. Revenues of €1.3 million for the first nine months of 2024. On July 18, 2024, Inventiva issued royalty certificates for an amount of €20.1 million. Considering the receipt of €94.1 million in gross proceeds from the closing of the first part of the first tr |
|
| November 20, 2024 |
Combined General Meeting of December 11, 2024 - Availability of the preparatory documents EXHIBIT 99.1 Combined General Meeting of December 11, 2024 - Availability of the preparatory documents Daix (France), Long Island City (New York, United States), November 20, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ( |
|
| November 20, 2024 |
EXHIBIT 99.1 Statement of total voting rights and shares forming the company’s share capital as of November 4, 2024 Article R. 22-10-23 of the French Commercial Code Market : Euronext Paris ISIN code / Mnemo : FR0013233012 / IVA Web site : www.inventivapharma.com Date Number of Shares Outstanding Total voting rights, gross (1) Total voting rights, net (2) November 4, 2024 87 077 695 100 059 052 99 |
|
| November 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, |
|
| November 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, |
|
| November 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, |
|
| November 15, 2024 |
EXHIBIT 99.1 Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session Data will be presented on Monday, November 18th as a late breaker poster at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 in S |
|
| November 14, 2024 |
Exhibit 99.2 INVENTIVA S.A. Ordinary and Extraordinary General Meeting of Inventiva S.A. to be held on December 11, 2024 Instructions for beneficial owners of American Depositary Shares (“ADSs”) Beneficial owners of ADSs who wish to submit their votes in connection with the General Meeting of Inventiva to be held on December 11, 2024 should consult the voting instruction form delivered to them by |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2024 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant’s name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address of principal executiv |
|
| November 14, 2024 |
Exhibit 99.1 Copyright © 2024 BetaNXT, Inc. or its affiliates. All Rights Reserved styleIPC Instructions to The Bank of New York Mellon, as Depositary (Must be received prior to 12:00 PM Eastern Time December 4, 2024) The undersigned Holder of American Depositary Receipts (“Receipts”) of Inventiva S.A. (the “Company”) hereby requests and instructs The Bank of New York Mellon, as Depositary, to vot |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2024 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant’s name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address of principal executiv |
|
| November 4, 2024 |
Exhibit 99.1 Free translation for information purpose only INVENTIVA Société Anonyme with a Board of Directors With a share capital of EUR 870,776.95 Registered office: 50, rue de Dijon, 21121 Daix 537 530 255 Trade and Companies Registry of Dijon NOTICE OF MEETING TO THE ORDINARY AND EXTRAORDINARY GENERAL MEETING DATED DECEMBER 11, 2024 The shareholders of INVENTIVA (the "Company") are hereby inf |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, a |
|
| October 30, 2024 |
EXHIBIT 99.1 Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data. The recommendation was based on the unblinded review by the DMC of safety data |
|
| October 21, 2024 |
SC 13D/A 1 nea17-inventiva18892.htm NEW ENTERPRISE ASSOCIATES 17, L.P. - INVENTIVA S.A. 13D/A(#2) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Inventiva S.A. (Name of Issuer) Ordinary Shares, €.01 par value per share (Title of Class of Securities) 46124U107 (CUSIP Number) Stephanie Brecher New Ente |
|
| October 21, 2024 |
SC 13D/A 1 sc13da307422iva10212024.htm AMENDMENT NO. 3 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 3)1 Inventiva S.A. (Name of Issuer) Ordinary Shares, nominal value €0.01 per share ( |
|
| October 15, 2024 |
Subscription Agreement for T1 [Shares] [Pre-Funded Warrants] Exhibit 99.1 Subscription Agreement for T1 [Shares] [Pre-Funded Warrants] INVENTIVA S.A. 50, rue de Dijon 21121 Daix France Inventiva S.A., a société anonyme organized under the laws of the French Republic, with a share capital of €524,771.88, consisting of 52,477,188 ordinary shares of €0.01 nominal value each (the “Ordinary Shares” and each, an “Ordinary Share”), and registered with the Commerce |
|
| October 15, 2024 |
Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study Exhibit 99.4 PRESS RELEASE Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study ► Inventiva secures €94.1 million of a multi-tranche equity financing of up to €348 million, subject to satisfaction of specified conditions, from both new and existing investors, and up to $30 million in milestone payments relating to equity financing pursuant to amendment to li |
|
| October 15, 2024 |
Table of Contents Exhibit 99.1 INVENTIVA S.A. A joint-stock company (société anonyme) with a share capital of 524,771.88 euros Registered office: 50, rue de Dijon, 21121 Daix, France Dijon Trade and Companies Register 537 530 255 INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 Table of Contents Table of contents 1. Interim Financial Report 3 1.1. General overview of activities 3 1. |
|
| October 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant’s name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address of principal executive |
|
| October 15, 2024 |
AMENDMENT No 4 TO THE EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT Exhibit 99.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT (INDICATED BY [***]) HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT INVENTIVA S.A. TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT No 4 TO THE EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT This FOURTH AMENDMENT TO THE EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT (this “Amendment #4”) is entered into as of |
|
| October 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2024 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant’s name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address of principal executive |
|
| September 25, 2024 |
Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results EXHIBIT 99.1 Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results Recruitment in NATiV3 clinical trial progresses with over 85% of the targeted number of patients enrolled in the main cohort and a statistical powering of the study expected to be superior to 95% for both doses evaluated in the trial. Baseline characteristics of patients randomized in the |
|
| September 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, |
|
| July 31, 2024 |
Inventiva Reports Preliminary 2024 First-Half Financial Information1 EXHIBIT 99.1 Inventiva Reports Preliminary 2024 First-Half Financial Information1 Cash and cash equivalents at €10.1 million as of June 30, 2024, compared to cash and cash equivalents at €26.9 million, €0.012 million of short-term deposits and €9.03 million of long-term deposits as of December 31, 2023. On July 18, 2024, Inventiva issued royalty certificates subscribed by Samsara BioCapital and ex |
|
| July 31, 2024 |
6-K 1 f6k073124.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Addr |
|
| July 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 2)1 Inventiva S.A. (Name of Issuer) Ordinary Shares, nominal value €0.01 per share (Title of Class of Securities) 46124U107 (CUSIP Number) JAMES KRATKY BVF |
|
| July 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2024 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant’s name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address of principal executive of |
|
| July 18, 2024 |
Royalty Certificate Subscription Agreement Exhibit 99.1 Royalty Certificate Subscription Agreement INVENTIVA 50, rue de Dijon 21121 Daix France The undersigned, [•] (the "Subscriber") hereby confirms its agreement with you as follows: 1. This Royalty Certificate Subscription Agreement (including the annexes attached hereto, the "Agreement" or the “Subscription Agreement”) is made as of the date set forth below between Inventiva S.A., a soc |
|
| July 18, 2024 |
Inventiva announces a €20.1 million issuance of royalty certificates Exhibit 99.2 Inventiva announces a €20.1 million issuance of royalty certificates ► Royalty certificates subscribed by Samsara BioCapital and existing shareholders (BVF Partners, NEA, Sofinnova and Yiheng). ► Royalty of 3% on future net sales of lanifibranor in the United States of America, the European Union and the United Kingdom over a 14-year term. ► Cash runway extended through September 2024 |
|
| July 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, and |
|
| July 5, 2024 |
EXHIBIT 99.1 Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position Recruitment in NATiV3 clinical trial continues in both cohorts with over 80% of the targeted number of patients enrolled in the main cohort and 100% in the exploratory cohort of NATiV3. Analysis of the baseline characteristics of all patients random |
|
| June 21, 2024 |
Results of the votes of the Combined Shareholders’ General Meeting of June 20, 2024 EXHIBIT 99.1 Results of the votes of the Combined Shareholders’ General Meeting of June 20, 2024 Daix (France), Long Island City (New York, United States), on June 21, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohe |
|
| June 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, and |
|
| June 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, and |
|
| June 21, 2024 |
EXHIBIT 99.1 Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 20 June 2024 Daix, 21 June 2024 Pursuant to Article 241-2 of the AMF General Regulations (Règlement Général de l’Autorité des marchés financiers), the purpose of this description is to present the objectives and terms of the Company’s share repurchase program approved by the Ordinary General Meet |
|
| June 5, 2024 |
Exhibit 99.1 Translation for information purpose only INVENTIVA French société Anonyme with a Board of Directors with a share capital of EUR 524,771.88 Registered Office: 50, Rue de Dijon, 21121 Daix 537 530 255 Trade and Companies Register of Dijon Notice of meeting The shareholders of INVENTIVA are informed that the Ordinary and Extraordinary General Meeting will be held on June 20, 2024 at 9 a. |
|
| June 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2024 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant’s name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address of principal executive of |
|
| May 30, 2024 |
Combined General Meeting of June 20, 2024 - Availability of the preparatory documents EXHIBIT 99.1 Combined General Meeting of June 20, 2024 - Availability of the preparatory documents Daix (France), Long Island City (New York, United States), May 30, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, and t |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, and t |
|
| May 30, 2024 |
EXHIBIT 99.1 Statement of total voting rights and shares forming the company’s share capital as of May 13, 2024 Article R. 22-10-23 of the French Commercial Code Market : Euronext Paris ISIN code / Mnemo : FR0013233012 / IVA Web site : www.inventivapharma.com Date Number of Shares Outstanding Total voting rights, gross (1) Total voting rights, net (2) May 13, 2024 52 477 188 65 493 081 65 381 630 |
|
| May 21, 2024 |
Inventiva reports 2024 First Quarter Financial Information1 and provides a corporate update EXHIBIT 99.1 Inventiva reports 2024 First Quarter Financial Information1 and provides a corporate update Cash and cash equivalents at €11.0 million, short-term2 deposits at €0.1million, and long-term deposit at €19.1 million3 as of March 31, 2024, compared to €26.9 million, €0.01 million and €9.0 million as of December 31, 2023, respectively. The fourth scheduled DMC meeting recommended to continu |
|
| May 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, and t |
|
| May 16, 2024 |
EXHIBIT 99.1 Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data. The recommendation was based on the unblinded review by the DMC of saf |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, and t |
|
| May 13, 2024 |
EXHIBIT 99.1 Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor Improvements were observed for insulin resistance (insulin levels, HOMA-IR), lipid metabolism (triglycerides, HDL-cholesterol, apolipoproteins), contro |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2024 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant’s name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address of principal executive off |
|
| May 13, 2024 |
Exhibit 99.1 Translation for information purpose only INVENTIVA Société Anonyme with a Board of Directors With a share capital of EUR 524,771.88 Registered Office: 50, Rue de Dijon, 21121 Daix 537 530 255 Trade and Companies Register of Dijon Notice of meeting to the Ordinary and Extraordinary General Meeting dated June 20, 2024 The shareholders of INVENTIVA (the "Company") are informed that the O |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, and t |
|
| May 3, 2024 |
SC 13D/A 1 nea17-inventiva18830.htm NEW ENTERPRISE ASSOCIATES 17, L.P. - INVENTIVA S.A. 13D/A(#1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Inventiva S.A. (Name of Issuer) Ordinary Shares, €.01 par value per share (Title of Class of Securities) 46124U107 (CUSIP Number) Stephanie Brecher New Ente |
|
| April 3, 2024 |
Exhibit 4.8 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT (INDICATED BY [***]) HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT INVENTIVA S.A. TREATS AS PRIVATE OR CONFIDENTIAL. EXCLUSIVE LICENSE AGREEMENT THIS EXCLUSIVE LICENSE AGREEMENT (the “Agreement”) is entered into as of September 20th, 2023 (the “Effective Date”), by and between INVENTIVA S.A., a company i |
|
| April 3, 2024 |
Exhibit 4.1 Summary of BSA Plans Share warrants (bons de souscription d’actions), or BSAs, entitle a holder to exercise the warrant for the underlying vested shares at an exercise price per share determined by our board of directors and at least equal to the fair market value of an ordinary share on the date of grant. In addition to any exercise price payable by a holder upon the exercise of any s |
|
| April 3, 2024 |
Exhibit 13.1 Certification by the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 |
|
| April 3, 2024 |
Exhibit 4.3 Summary of Free Share Plans Free Shares (actions gratuites) are allotted for free to holders at an issuance price equal to the par value as set forth in the by-laws (€0.01). The issuance of the Free Shares will occur automatically at the end of the vesting period, by way of a capital increase, which will be realized by debiting the unavailable reserve (réserve non disponible) establish |
|
| April 3, 2024 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 KPMG S.A. Tour Eqho 2 avenue Gambetta CS 60055 92066 Paris la Défense Cedex Telephone: +33 (0)1 55 68 68 68 Telefax: +33 (0)1 55 68 73 00 Internet: www.kpmg.fr Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the registration statement (No. 333-258369) on Form F-3 of our report dated April 2, 2024, with respect to the consolidate |
|
| April 3, 2024 |
DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Exhibit 2.4 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description sets forth certain material terms and provisions of the securities of Inventiva S.A. (“Inventiva,” the “Company,” “we,” “us” and “our”) that are registered under Section 12 of the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”). This descrip |
|
| April 3, 2024 |
Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rule 13a-14(a) or Rule 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Frédéric Cren, certify that: 1.I have reviewed this annual report on Form 20-F of Inventiva S.A.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or om |
|
| April 3, 2024 |
Exhibit 1.1 INVENTIVA Société anonyme à Conseil d’administration with a share capital of €521,158.07 Registered office: 50 Rue de Dijon, 21121, Daix, France Dijon Trade and Companies Register 537 530 255 ARTICLES OF ASSOCIATION UPDATED TO REFLECT THE CHIEF EXECUTIVE OFFICER’S DECISIONS OF 8th December 2023 PART I FORM - NAME - OBJECTS - REGISTERED OFFICE - TERM ARTICLE 1. FORM The company (the “Co |
|
| April 3, 2024 |
Exhibit 4.4 Performance Units (PAGUP) On May 25, 2023, the Company's board of directors (the “Board”) granted 300,000 free performance units, or PAGUPs, to Mr. Frédéric Cren, the Chief Executive Officer and Chairman of the Board of the Company. The purpose of this plan is to provide Mr. Cren with a long-term incentive scheme under economically comparable conditions to those granted to Pierre Broqu |
|
| April 3, 2024 |
Exhibit 4.9 Execution Version SHAREHOLDERS AGREEMENT Catalys Pacific Fund II, LP (“Catalys”), Inventiva S.A. (“Inventiva”) and Hepalys Pharma, Inc. (the “Company”) enter into this Shareholders Agreement (this “Agreement”) on September 20th, 2023 in respect of the Company on the terms and conditions set forth below. RECITALS (A) The parties entered into a Shareholders Agreement on May 11, 2023 (the |
|
| April 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF |
|
| April 3, 2024 |
Exhibit 4.2 Summary of BSPCE Plans Founder’s share warrants (bons de souscription de parts de créateur d’entreprise), or BSPCEs, entitle a holder to exercise the warrant for the underlying vested shares at an exercise price per share determined by our Board of Directors and at least equal to the fair market value of an ordinary share on the date of grant. Because one of the conditions to be eligib |
|
| April 3, 2024 |
Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rule 13a-14(a) or Rule 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Jean Volatier, certify that: 1. I have reviewed this annual report on Form 20-F of Inventiva S.A.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or o |
|
| April 3, 2024 |
INVENTIVA S.A. INCENTIVE COMPENSATION RECOUPMENT POLICY Exhibit 97 INVENTIVA S.A. INCENTIVE COMPENSATION RECOUPMENT POLICY 1.INTRODUCTION The Board of Directors (the “Board”) of Inventiva S.A. a société anonyme organized under the laws of France (the “Company”), has determined that it is in the best interests of the Company and its shareholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing for the Company’s recoupment |
|
| March 27, 2024 |
Inventiva reports its 2023 full-year results EXHIBIT 99.1 Inventiva reports its 2023 full-year results Revenues at €17.5 million for the full year of 2023 up 43.4% compared to €12.2 million for 2022 Cash and cash equivalents at €26.9 million, short-term deposits at €0.01 million1, and long-term deposit at €9.0 million2 as of December 31, 2023, compared to €86.7 million, €1.0 million, and €0.7 million respectively, as of December 31, 2022 In |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, and |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, and |
|
| March 18, 2024 |
EdgarFiling EXHIBIT 99.1 Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D LEGEND achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lanifibranor with empagliflozin arm compared to placebo. Statistical significance was a |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, and |
|
| March 7, 2024 |
EXHIBIT 99.1 Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed Inventiva has lifted the voluntary pause on screening and randomization in the NATiV3 clinical trial following the approval from the US central IRB of the amended protocol and ICF. Screening of patients is resuming in sites operating under central IRB in the US. Othe |
|
| February 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, |
|
| February 15, 2024 |
EXHIBIT 99.1 Inventiva reports preliminary 2023 fiscal year financial Informationˆ and provides an update on its clinical trial NATiV3 Revenues of €17.5 million for the full year of 2023, compared to €12.2 million for 2022 Cash and cash equivalents at €26.9 million, short-term deposits at € 0.01 million2, and long-term deposit at €9.0 million3 as of December 31, 2023, compared to €86.7 million, €1 |
|
| February 14, 2024 |
SC 13G/A 1 yihengiva13ga1.htm YIHENGIVA13GA1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.1)* Inventiva S.A. (Name of Issuer) Ordinary shares, par value $0.01 per share (Title of Class of Securities) 46124U107 (CUSIP Number) Yiheng Capital Management, L.P. 101 California Street, Suite 2880 San Francisco |
|
| February 9, 2024 |
US46124U1079 / INVENTIVA SA-ADR / Sofinnova Crossover I - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 3) * Inventiva S.A. (Name of Issuer) Ordinary Shares, nominal value €0.01 per share (Title of Class of Securities) 46124U107 (CUSIP Number) Decem |
|
| February 9, 2024 |
US46124U1079 / INVENTIVA SA-ADR / Sofinnova Crossover I - EXHIBIT 1 Joint Filing Agreement EX-99.1 2 tm245335d1ex-1.htm EXHIBIT 1 Exhibit 1 Joint Filing Agreement In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the ordinary shares of Inventiva S.A. and further agree that this agreement be included as an |
|
| January 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, a |
|
| January 10, 2024 |
EXHIBIT 99.1 Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bank Inventiva intends to use the proceeds to fund part of its ongoing pivotal NATiV3 Phase III clinical trial evaluating lanifibranor in patients with NASH. This second tranche carries an interest rate of 7% annually and has a maturity of 3 years and a repayment in fine |
|
| December 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, |
|
| December 20, 2023 |
EXHIBIT 99.1 Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program The first patient was randomized in China in the NATiV3 Phase III clinical trial, triggering a milestone payment of $3 million from CTTQ to Inventiva. With this milestone payment Inventiva expects to have met the operational and fi |
|
| November 21, 2023 |
Inventiva reports 2023 Third Quarter Financial Information1 EXHIBIT 99.1 Inventiva reports 2023 Third Quarter Financial Information1 Cash and cash equivalents at €43.8 million, short-term deposits at €0.03 million2, and long-term deposit at €5.0 million3 as of September 30, 2023, compared to €86.7 million, €1.0 million and €0.7 million as of December 31, 2022, respectively Revenues of €1.9 million for the first nine months of 2023, compared to €0.1 million |
|
| November 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, |
|
| October 3, 2023 |
Table of Contents Exhibit 99.1 INVENTIVA S.A. A joint-stock company (société anonyme) with a share capital of 517,528.07 euros Registered office: 50, rue de Dijon, 21121 Daix, France Dijon Trade and Companies Register 537 530 255 INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2023 Table of Contents Table of contents 1. Interim Financial Report 3 1.1. General overview of activities 3 1. |
|
| October 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A (Amendment No. 1) REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2023 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant’s name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address |
|
| September 29, 2023 |
Exhibit 1.1 Execution Version SALES AGREEMENT September 28, 2023 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Inventiva S.A., a société anonyme organized under the laws of France and registered with the Register of Commerce and Companies (Registre du Commerce et des Sociétés) of Dijon under number 537 530 255 (the “Company”), proposes, subject to the terms a |
|
| September 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2023 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant’s name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address of principal executi |
|
| September 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2023 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant’s name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address of principal execut |
|
| September 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, |
|
| September 28, 2023 |
Table of Contents Exhibit 99.1 INVENTIVA S.A. A joint-stock company (société anonyme) with a share capital of 517,528.07 euros Registered office: 50, rue de Dijon, 21121 Daix, France Dijon Trade and Companies Register 537 530 255 INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2023 Table of Contents Table of contents 1. Interim Financial Report 3 1.1. General overview of activities 3 1. |
|
| September 28, 2023 |
Inventiva reports its 2023 first-half financial results and provides a corporate update EXHIBIT 99.1 Inventiva reports its 2023 first-half financial results and provides a corporate update Cash and cash equivalents at €31.2 million, short-term deposits at €0.05 million1, and long-term deposit at €9.3 million2, as of June 30, 2023, compared to €86.7 million, €1.0 million and €0.7 million as of December 31, 2022, respectivel Revenues amounted to €1.9 million for the first half of 2023 |
|
| September 28, 2023 |
Up to $58,000,000 American Depositary Shares representing Ordinary Shares TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration No. 333-258369 PROSPECTUS SUPPLEMENT (To Prospectus Dated August 6, 2021) Up to $58,000,000 American Depositary Shares representing Ordinary Shares We have entered into a sale agreement, or Sales Agreement, with Cowen and Company, LLC, or TD Cowen, relating to the sale of American Depositary Shares, or ADSs, each ADS representing o |
|
| September 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 Inventiva S.A. (Name of Issuer) Ordinary Shares, nominal value €0.01 per share (Title of Class of Securities) 46124U107 (CUSIP Number) JAMES KRATKY BVF |
|
| September 20, 2023 |
EdgarFiling EXHIBIT 99.1 Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea Hepalys Pharma, Inc. is a new company created by Catalys Pacific and in which Inventiva has a 30% ownership position. Under the exclusive licensing agreement, Inventiva will receive a $10 million upfront payment, and is eligible to re |
|
| September 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Inventiva S.A. (Name of Issuer) Ordinary shares, par value €0.01 per share (Title of Class of Securities) 46124U107 (CUSIP Number) August 30, 2023 (Date of Event Which Requires Filing this Statement) Check the appropriate box to designate the rule pursuan |
|
| August 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2023 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant’s name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address of principal executive |
|
| August 31, 2023 |
Royalty Certificate Subscription Agreement Exhibit 99.2 Royalty Certificate Subscription Agreement INVENTIVA 50, rue de Dijon 21121 Daix France The undersigned, [•] (the “Subscriber”) hereby confirms its agreement with you as follows: 1. This Royalty Certificate Subscription Agreement (including the annexes attached hereto, the “Agreement”) is made as of the date set forth below between Inventiva S.A., a société anonyme organized under the |
|
| August 31, 2023 |
Exhibit 99.1 Subscription Agreement INVENTIVA 50, rue de Dijon 21121 Daix France The undersigned, [•] (the “Subscriber”) hereby confirms its agreement with you as follows: 1. This Subscription Agreement (including the annexes attached hereto, the “Agreement”) is made as of the date set forth below between Inventiva S.A., a société anonyme organized under the laws of the French Republic, with a sha |
|
| August 31, 2023 |
Exhibit 99.3 PRESS RELEASE Inventiva announces a financing of approximately €35.7 million from new and existing investors, consisting of a €30.6 million reserved capital increase and a €5.1 million issuance of royalty certificates Daix (France), Long Island City (New York, United States), August 31, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutic |
|
| July 27, 2023 |
Inventiva Reports Preliminary 2023 First-Half Financial Information1 and Business update EXHIBIT 99.1 Inventiva Reports Preliminary 2023 First-Half Financial Information1 and Business update Cash and cash equivalents at €31.2 million, short-term deposits at €0.05 million2, and long-term deposit at €9.3 million3 as of June 30, 2023, compared to €86.7 million, €1.0 million and €0.7 million as of December 31, 2022, respectively Revenues of €1.9 m in H1 2023, compared to €0.1 million for |
|
| July 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, and |
|
| June 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, and |
|
| June 14, 2023 |
EXHIBIT 99.1 Inventiva announces positive topline results from the investigator-initiated Phase II clinical trial evaluating lanifibranor in patients with T2D and NAFLD Lanifibranor 800mg achieved the primary efficacy endpoint demonstrating a 44% reduction of hepatic fat measured by proton magnetic resonance spectroscopy (1H-MRS) following 24 weeks of treatment in patients with nonalcoholic fatty |
|
| May 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, and t |
|
| May 26, 2023 |
Results of the votes of the Combined Shareholders’ General Meeting of May 25, 2023 EdgarFiling EXHIBIT 99.1 Results of the votes of the Combined Shareholders’ General Meeting of May 25, 2023 Daix (France), Long Island City (New York, United States), May 26, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other dis |
|
| May 25, 2023 |
EdgarFiling EXHIBIT 99.1 Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 25 May 2023 Daix, 25 May 2023 Pursuant to Article 241-2 of the AMF General Regulations (Règlement Général de l’Autorité des marchés financiers), the purpose of this description is to present the objectives and terms of the Company’s share repurchase program approved by the Ordinary Ge |
|
| May 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, and t |
|
| May 25, 2023 |
EdgarFiling EXHIBIT 99.1 Inventiva announces that its partner Sino Biopharm received IND approval from the NMPA to initiate clinical trial with lanifibranor in China Chia Tai Tianqing Pharmaceutical Group Co., Ltd., a Sino Biopharm’s subsidiary, receives IND approval from the NMPA to initiate the clinical development in mainland China of lanifibranor in NASH Sino Biopharm will participate in the o |
|
| May 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, and t |
|
| May 16, 2023 |
Inventiva reports 2023 First Quarter Financial Information1 and provides a corporate update EXHIBIT 99.1 Inventiva reports 2023 First Quarter Financial Information1 and provides a corporate update Cash and cash equivalents at €56.3 million, short-term deposits at €0.7 million2, and long term deposit at €9.3 million3 as of March 31, 2023, compared to €86.7 million, €1.0 million and €0.7 million as of December 31, 2022, respectively Improvements on NATiV3 Phase III clinical trial with lani |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, and t |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2023 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant’s name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address of principal executive off |
|
| May 5, 2023 |
Exhibit 99.1 Translation for information purpose only INVENTIVA French société Anonyme with a Board of Directors with a share capital of EUR 421,341.69 Registered Office: 50, Rue de Dijon, 21121 Daix 537 530 255 Trade and Companies Register of Dijon Notice of meeting The shareholders of INVENTIVA are informed that the Ordinary and Extraordinary General Meeting will be held on May 25, 2023 at 2 p.m |
|
| May 4, 2023 |
EdgarFiling EXHIBIT 99.2 Statement of total voting rights and shares forming the company’s share capital as of April 17, 2023 Article R. 22-10-23 of the French Commercial Code Market : Euronext Paris ISIN code / Mnemo : FR0013233012 / IVA Web site : www.inventivapharma.com Date Number of Shares Outstanding Total voting rights, gross (1) Total voting rights, net (2) 17 April 2023 42 134 169 55 141 |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, and t |
|
| May 4, 2023 |
Combined General Meeting of May 25, 2023. Availability of the preparatory documents EdgarFiling EXHIBIT 99.1 Combined General Meeting of May 25, 2023. Availability of the preparatory documents Daix (France), Long Island City (New York, United States), May 4, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) |
|
| April 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2023 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant’s name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address of principal executive o |
|
| April 25, 2023 |
Exhibit 99.1 23201 Inventiva SA VIF Proof 3 Ordinary and Extraordinary General Meeting of Inventiva S.A. Date: May 25, 2023 See Voting Instruction On Reverse Side. Please make your marks like this: x Use pen only Ordinary and Extraordinary General Meeting of Inventiva S.A. to be held May 25, 2023 For Holders as of April 17, 2023 All votes must be received by 12:00 PM Eastern Time May 19, 2023. OGM |
|
| April 25, 2023 |
Exhibit 99.2 INVENTIVA S.A. Ordinary and Extraordinary General Meeting of Inventiva S.A. to be held on May 25, 2023 Instructions for beneficial owners of American Depositary Shares (“ADSs” ) Beneficial owners of ADSs who wish to submit their votes in connection with the General Meeting of Inventiva to be held on May 25, 2023 should consult the voting instruction form delivered to them by The Bank |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2023 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant’s name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address of principal executive o |
|
| April 17, 2023 |
Exhibit 99.1 Translation for information purpose only INVENTIVA Société Anonyme with a Board of Directors With a share capital of EUR 421,341.69 Registered Office : 50, Rue de Dijon, 21121 Daix 537 530 255 Trade and Companies Register of Dijon Notice of meeting to the Ordinary and Extraordinary General Meeting dated May 25, 2023 The shareholders of INVENTIVA (the "Company") are informed that the O |
|
| March 30, 2023 |
Summary of BSA 2017, BSA 2018 and BSA 2019, BSA 2019 bis, BSA 2019 ter, and BSA 2021 Plans Exhibit 4.1 Summary of BSA Plans Share warrants (bons de souscription d’actions), or BSAs, entitle a holder to exercise the warrant for the underlying vested shares at an exercise price per share determined by our board of directors and at least equal to the fair market value of an ordinary share on the date of grant. In addition to any exercise price payable by a holder upon the exercise of any s |
|
| March 30, 2023 |
Summary of BSPCE 2013-1 and BSPCE 2021 Plans Exhibit 4.2 Summary of BSPCE Plans Founder’s share warrants (bons de souscription de parts de créateur d’entreprise), or BSPCEs, entitle a holder to exercise the warrant for the underlying vested shares at an exercise price per share determined by our board of directors and at least equal to the fair market value of an ordinary share on the date of grant. Founder’s share warrants may only be issue |
|
| March 30, 2023 |
Summary of AGA 2021-1, AGA 2021 bis and AGA 2022 Free Share Plans (English Translation) EX-4.3 6 iva-20221231xex4d3.htm EXHIBIT 4.3 Exhibit 4.3 Summary of Free Share Plans Free Shares (actions gratuites) are allotted for free to holders at an issuance price equal to the par value as set forth in the by-laws (€0.01). The issuance of the Free Shares will occur automatically at the end of the vesting period, by way of a capital increase, which will be realized by debiting the unavailabl |
|
| March 30, 2023 |
Exhibit 2.4 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description sets forth certain material terms and provisions of the securities of Inventiva S.A. (“Inventiva,” the “Company,” “we,” “us” and “our”) that are registered under Section 12 of the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”). This descrip |
|
| March 30, 2023 |
Exhibit 13.2 CERTIFICATION OF CFO PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Jean Volatier, Chief Financial Officer of Inv |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF |
|
| March 30, 2023 |
Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Jean Volatier, certify that: 1. I have reviewed this annual report on Form 20-F of Inventiva S.A. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a mate |
|
| March 30, 2023 |
Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Frédéric Cren, certify that: 1. I have reviewed this annual report on Form 20-F of Inventiva S.A. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a mate |
|
| March 30, 2023 |
Exhibit 15.1 KPMG S.A. Téléphone : +33 (0)1 55 68 68 68 Tour EQHO Télécopie : +33 (0)1 55 68 73 00 2 Avenue Gambetta Site internet : www.kpmg.fr CS 60055 92066 Paris la Défense Cedex France Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the registration statement (No. 333-258369) on Form F-3 of our report dated March 27, 2023, with respect |
|
| March 30, 2023 |
Bylaws of the registrant (English translation). Exhibit 1.1 INVENTIVA Société anonyme à Conseil d’administration with a share capital of €421,341.69 Registered office: 50 Rue de Dijon, 21121, Daix, France Dijon Trade and Companies Register 537 530 255 ARTICLES OF ASSOCIATION UPDATED TO REFLECT THE CHIEF EXECUTIVE OFFICER’S DECISIONS OF 6th July 2022 PART I FORM - NAME - OBJECTS - REGISTERED OFFICE - TERM ARTICLE 1.FORM The company (the “Company |
|
| March 30, 2023 |
Exhibit 13.1 CERTIFICATION OF CEO PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Frédéric Cren, Chief Executive Officer of Inv |
|
| March 29, 2023 |
Inventiva reports its 2022 full-year results EdgarFiling EXHIBIT 99.1 Inventiva reports its 2022 full-year results Cash and cash equivalents at €86.7 million and short term deposits at €1 million as of December 31, 2022 compared to €86.6 million and €8.8 million, respectively as of December 31, 2021 Inventiva entered into a license and collaboration agreement with Sino Biopharm a leading Chinese pharmaceutical group, through CTTQ, to develop |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, and |
|
| February 14, 2023 |
SC 13G 1 yiheng13gIVA.htm YIHENG13GIVA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Inventiva S.A. (Name of Issuer) Ordinary shares, par value $0.01 per share (Title of Class of Securities) 46124U107 (CUSIP Number) Yiheng Capital Management, L.P. 101 California Street, Suite 2880 San Francisco, CA 94 |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, |
|
| February 14, 2023 |
Inventiva reports preliminary financial results for Full-Year 20221 EXHIBIT 99.1 Inventiva reports preliminary financial results for Full-Year 20221 Daix (France), Long Island City (New York, United States), February 14, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (“NASH”) and |
|
| February 13, 2023 |
US46124U1079 / INVENTIVA SA-ADR / Sofinnova Crossover I - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 2) * Inventiva S.A. (Name of Issuer) Ordinary Shares, nominal value €0.01 per share (Title of Class of Securities) 46124U107 (CUSIP Number) Decem |
|
| February 13, 2023 |
EX-99.1 2 tm236518d1ex99-1.htm EXHIBIT 99.1 CUSIP NO. 46124U107 Page 15 of 15 Pages Joint Filing Agreement In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the ordinary shares of Inventiva S.A. and further agree tha |
|
| January 26, 2023 |
Results of the votes of the Combined Shareholders’ General Meeting of January 25, 2023 EdgarFiling EXHIBIT 99.1 Results of the votes of the Combined Shareholders’ General Meeting of January 25, 2023 Daix (France), Long Island City (New York, United States), January 26, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and o |
|
| January 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, a |
|
| January 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2023 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant’s name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address of principal executive |
|
| January 6, 2023 |
Exhibit 99.1 Translation for information purpose only INVENTIVA Soci?t? Anonyme with a Board of Directors With a share capital of EUR 421,341.69 Registered Office: 50, Rue de Dijon, 21121 Daix 537 530 255 Trade and Companies Register of Dijon Notice of meeting The shareholders of INVENTIVA are informed that the Ordinary and Extraordinary General Meeting will be held on January 25, 2023 at 2 p.m., |
|
| January 4, 2023 |
EXHIBIT 99.1 Inventiva announces changes to the clinical development of lanifibranor, including plans for a new Phase III trial in patients with NASH and compensated cirrhosis Proposed changes are expected to be beneficial to the lanifibranor clinical program by reducing the number of biopsies and the trial duration, eventually offering all patients in the trial access to treatment and potentially |
|
| January 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, a |
|
| January 3, 2023 |
Exhibit 99.1 Please separate carefully at the perforation and return just this portion in the envelope provided. Ordinary and Extraordinary General Meeting of Inventiva S.A. Ordinar y an d Extraordinar y Genera l Meetin g o f Inventiv a S.A. to be held January 25, 2023 Date: January 25, 2023 See Voting Instruction On Reverse Side. Please make your marks like this: Use pen only For Holders as of De |
|
| January 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 3, 2023 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant?s name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address of principal executive office) Indic |
|
| January 3, 2023 |
Combined General Meeting of January 25, 2023 Availability of the preparatory documents EX-99.3 4 tm2233812d1ex99-3.htm EXHIBIT 99.3 Exhibit 99.3 PRESS RELEASE Combined General Meeting of January 25, 2023 Availability of the preparatory documents Daix (France), Long Island City (New York, United States), January 3, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment |
|
| January 3, 2023 |
Exhibit 99.4 PRESS RELEASE Statement of total voting rights and shares forming the company?s share capital as of December 19, 2022 Article R. 22-10-23 of the French Commercial Code Market : Euronext Paris ISIN code / Mnemo : FR0013233012 / IVA Web site : www.inventivapharma.com Date Number of Shares Outstanding Total voting rights, gross (1) Total voting rights, net (2) December 19, 2022 42 134 16 |
|
| January 3, 2023 |
EX-99.2 3 tm2233812d1ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 INVENTIVA S.A. Ordinary and Extraordinary General Meeting of Inventiva S.A. to be held on January 25, 2023 Instructions for beneficial owners of American Depositary Shares (“ADSs” ) Beneficial owners of ADSs who wish to submit their votes in connection with the General Meeting of Inventiva to be held on January 25, 2023 should consult the v |
|
| December 19, 2022 |
Exhibit 99.1 Translation for information purpose only INVENTIVA Société Anonyme with a Board of Directors With a share capital of EUR 421,341.69 Registered Office : 50, Rue de Dijon, 21121 Daix 537 530 255 Trade and Companies Register of Dijon Notice of meeting to the Ordinary and Extraordinary General Meeting dated January 25, 2023 The shareholders of INVENTIVA are informed that the Ordinary and |
|
| December 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2022 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant’s name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address of principal executiv |
|
| December 12, 2022 |
Inventiva draws down €25 million tranche under Finance Contract with the European Investment Bank EdgarFiling EXHIBIT 99.1 Inventiva draws down €25 million tranche under Finance Contract with the European Investment Bank Inventiva intends to use the proceeds to fund part of the pivotal Phase III clinical trial evaluating lanifibranor in patients with NASH The €25 million supports Inventiva’s anticipated cash runway1 through the fourth quarter of 2023 Daix (France), Long Island City (New York, |
|
| December 12, 2022 |
6-K 1 f6k121222.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 ( |
|
| November 21, 2022 |
Inventiva announces a new Director of the Board of Directors EXHIBIT 99.1 Inventiva announces a new Director of the Board of Directors Daix (France), Long Island City (New York, United States), November 21, 2022 ? Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of nonalcoholic steatohepatitis (NASH) and other diseases with significant unmet m |
|
| November 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, |
|
| November 10, 2022 |
Inventiva reports 2022 Third Quarter Financial Informationˆ EXHIBIT 99.1 Inventiva reports 2022 Third Quarter Financial Information? Cash position2 at ?72.6m as of September 30, 2022, not including the $12.6 million upfront payment received from Sino Biopharm on November 4, 2022 Revenues of ?0.1m for the first nine months of 2022 Daix (France), Long Island City (New York, United States), November 10, 2022 ? Inventiva (Euronext Paris and Nasdaq: IVA) (the ? |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, |
|
| October 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2022 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, a |
|
| October 31, 2022 |
Inventiva provides an update on the development of cedirogant by AbbVie Exhibit 99.1 PRESS RELEASE Inventiva provides an update on the development of cedirogant by AbbVie Daix (France), Long Island City (New York, United States), October 31, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharid |
|
| September 27, 2022 |
6-K 1 tm2226712d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2022 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant’s name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 |
|
| September 27, 2022 |
EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT Exhibit 99.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT (INDICATED BY [***]) HAS BEEN OMITTED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT INVENTIVA S.A. TREATS AS PRIVATE OR CONFIDENTIAL. EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT This Exclusive License and Collaboration Agreement (the ?Agreement?) is entered into as of Sept |
|
| September 22, 2022 |
Exhibit 99.1 Inventiva and Sino Biopharm announce licensing and collaboration agreement to develop and commercialize lanifibranor in Greater China ? Sino Biopharm a leading Chinese pharmaceutical group, through CTTQ will oversee the development and commercialization of lanifibranor in Greater China ? Lanifibranor is an orally-available small molecule with breakthrough therapy designation from the |
|
| September 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, |
|
| September 22, 2022 |
Inventiva reports its 2022 first-half financial results and provides a corporate update Exhibit 99.3 PRESS RELEASE Inventiva reports its 2022 first-half financial results and provides a corporate update ? Cash position1 at ?87.2 million as of June 30, 2022, compared to ?95.4 million as of December 31, 2021 ? Receipt of a ?4 million milestone payment from Inventiva?s partner AbbVie for cedirogant Phase IIb clinical trial initiation accounted for in 2021 revenues and H1 2022 cash flow |
|
| September 22, 2022 |
Exhibit 99.2 INVENTIVA S.A. A joint-stock company (soci?t? anonyme) with a share capital of 421,341.69 euros Registered office: 50, rue de Dijon, 21121 Daix, France Dijon Trade and Companies Register 537 530 255 INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2022 Table of contents 1. ?????Interim Financial Report 2 1.1. General overview of activities 2 1.2. Significant events in first- |
|
| July 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, and |
|
| July 28, 2022 |
Inventiva Reports 2022 First-Half Financial Informationˆ EXHIBIT 99.1 Inventiva Reports 2022 First-Half Financial Information? Cash position2 at ?87.2 m as of June 30, 2022 Revenues of ?0.1 m in H1 2022 Inventiva entered into a finance loan and a warrant agreement for up to ?50 million with the European Investment Bank (EIB) Inventiva raised approximately ?14.6m through a combination of its At-The-Market program (for ?9.3m in gross proceeds) and new Sta |
|
| July 5, 2022 |
Exhibit 99.1 PRESS RELEASE Update on Inventiva's cash position and on the finance documentation with the European Investment Bank ? Inventiva successfully raised approximately ?14.6 million through a combination of its ATM Program for ?9.3 million and new State-backed bank financing for ?5.3 million ? In accordance with the terms of the credit facility announced on May 16, 2022, Inventiva entered |
|
| July 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, and |
|
| June 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, and |
|
| May 20, 2022 |
Results of the votes of the Combined Shareholders’ Meeting of May 19, 2022 Exhibit 99.1 PRESS RELEASE Results of the votes of the Combined Shareholders? Meeting of May 19, 2022 Daix (France), Long Island City (New York, United States), May 20, 2022 ? Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases |
|
| May 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, and t |
|
| May 19, 2022 |
Exhibit 99.1 PRESS RELEASE DESCRIPTION OF THE SHARE REPURCHASE PROGRAM AUTHORISED BY THE ORDINARY GENERAL MEETING OF 19 MAY 2022 Daix, May 19, 2022 Pursuant to Article 241-2 of the AMF General Regulations (R?glement G?n?ral de l?Autorit? des march?s financiers), the purpose of this description is to present the objectives and terms of the share repurchase program of Inventiva S.A. (the ?Company?) |
|
| May 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, and t |
|
| May 16, 2022 |
INVENTIVA (EGFF) Finance Contract between the European Investment Bank Inventiva S.A. 16 May 2022 Exhibit 99.2 Inventiva Contract number (FI No): 93637 Contract number (FI No): 94751 Serapis No: 2021-0353 INVENTIVA (EGFF) Finance Contract between the European Investment Bank and Inventiva S.A. 16 May 2022 WHEREAS: 6 Article 1 7 1.1 Interpretation 7 Article 2 16 2.1 Amount of Credit 16 2.2 Disbursement procedure 16 2.2.1 Tranches 16 2.2.2 Disbursement Offer 16 2.2.3 Disbursement Acceptance 16 2 |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2022 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant?s name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address of principal executive off |
|
| May 16, 2022 |
Inventiva secures a €50 million credit facility from the European Investment Bank Exhibit 99.1 PRESS RELEASE Inventiva secures a ?50 million credit facility from the European Investment Bank ? This credit facility is intended to support the progress and expansion of Inventiva?s pipeline ? The credit facility consists of two tranches of ?25 million each ? Credit agreement is part of the European Investment Bank?s strategy to support biotech companies developing a high-level of e |
|
| May 16, 2022 |
Inventiva reports 2022 First Quarter Financial Information and provides clinical development update EXHIBIT 99.1 Inventiva reports 2022 First Quarter Financial Information and provides clinical development update Cash position2 at ?80.5m as of March 31, 2022 The Group did not generate any revenue in Q1 2022 Signature of a ?50 million bullet credit facility agreement with the European Investment Bank Update on lanifibranor recruitment timing for Phase III trial in patients with NASH, as well as f |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant's name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address, including zip code, and t |
|
| May 2, 2022 |
Exhibit 99.1 Translation for information purpose only INVENTIVA Soci?t? Anonyme with a Board of Directors With a share capital of EUR 408,735.51 Registered Office: 50, Rue de Dijon, 21121 Daix 537 530 255 Trade and Companies Register of Dijon Notice of meeting The shareholders of INVENTIVA are informed that the Ordinary and Extraordinary General Meeting will be held on May 19, 2022 at 2 p.m., at: |
|
| May 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2022 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant?s name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address of principal executive off |
|
| April 28, 2022 |
Exhibit 99.2 PRESS RELEASE Statement of total voting rights and shares forming the company?s share capital as of April 11, 2022 Article R. 22-10-23 of the French Commercial Code Market : Euronext Paris ISIN code / Mnemo : FR0013233012 / IVA Web site : www.inventivapharma.com Date Number of Shares Outstanding Total voting rights, gross (1) Total voting rights, net (2) April 11, 2022 40 873 551 52 8 |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2022 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant?s name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address of principal executive o |
|
| April 28, 2022 |
Combined General Meeting of May 19, 2022 Availability of the preparatory documents Exhibit 99.1 PRESS RELEASE Combined General Meeting of May 19, 2022 Availability of the preparatory documents Daix (France), Long Island City (New York, United States), April 28, 2022 ? Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other |
|
| April 25, 2022 |
Exhibit 99.2 INVENTIVA Ordinary and Extraordinary General Meeting of Inventiva S.A. to be held on May 19, 2022 Instructions for beneficial owners of American Depositary Shares (?ADSs?) Beneficial owners of ADSs who wish to submit their votes in connection with the General Meeting of Inventiva to be held on May 19, 2022 should consult the voting instruction form delivered to them by The Bank of New |
|
| April 25, 2022 |
Exhibit 99.1 19570 Inventiva SA VIF Proof 3 Ordinary and Extraordinary General Meeting of Inventiva S.A. Date: May 19, 2022 See Voting Instruction On Reverse Side. Please make your marks like this: x Use pen only Ordinary and Extraordinary General Meeting of Inventiva S.A. to be held May 19, 2022 For Holders as of April 11, 2022 All votes must be received by 5:00 pm, Eastern Time May 13, 2022. Cop |
|
| April 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2022 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant?s name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address of principal executive o |
|
| April 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2022 Commission File Number: 001-39374 Inventiva S.A. (Translation of registrant?s name into English) 50 rue de Dijon 21121 Daix France +33 3 80 44 75 00 (Address of principal executive o |
|
| April 11, 2022 |
Exhibit 99.1 Translation for information purpose only INVENTIVA Soci?t? Anonyme with a Board of Directors With a share capital of EUR 408,735.51 Registered Office: 50, Rue de Dijon, 21121 Daix 537 530 255 Trade and Companies Register of Dijon Notice of meeting to the Ordinary and Extraordinary General Meeting dated May 19, 2022 The shareholders of INVENTIVA are informed that the Ordinary and Extra |
|
| March 11, 2022 |
Exhibit 12.2 SECTION 302 CERTIFICATION I, Jean Volatier, certify that: 1. I have reviewed this annual report on Form 20-F of Inventiva S.A.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with res |
|
| March 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 11, 2022 |
Exhibit 13.1 CERTIFICATION OF CEO PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Frédéric Cren, Chief Executive Officer of Inv |
|
| March 11, 2022 |
Exhibit 13.2 CERTIFICATION OF CFO PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Jean Volatier, Chief Financial Officer of Inv |
|
| March 11, 2022 |
Exhibit 12.1 SECTION 302 CERTIFICATION I, Frédéric Cren, certify that: 1. I have reviewed this annual report on Form 20-F of Inventiva S.A.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with res |
|
| March 11, 2022 |
Bylaws of the registrant (English translation). EX-1.1 2 iva-20201231xex1d1.htm EXHIBIT 1.1 Exhibit 1.1 INVENTIVA Société anonyme à Conseil d’administration with a share capital of €408,735.51 Registered office: 50 Rue de Dijon, 21121 Daix, France Dijon Trade and Companies Register 537 530 255 ARTICLES OF ASSOCIATION UPDATED TO REFLECT THE CHIEF EXECUTIVE OFFICER’S DECISIONS OF 1st October 2021 PART I FORM - NAME - OBJECTS - REGISTERED OFFICE - |
|
| March 11, 2022 |
Exhibit 15.1 ? ? ? ? ? ? KPMG Audit Tour EQHO 2 Avenue Gambetta CS 60055 92066 Paris la D?fense Cedex France ? T?l?phone :+33 (0)1 55 68 68 68 T?l?copie :+33 (0)1 55 68 73 00 Site internet :www.kpmg.fr ? ? Consent of Independent Registered Public Accounting Firm The Board of Directors Inventiva S.A. We consent to the incorporation by reference in the registration statement (No. 333-258369) on Form |
|
| March 8, 2022 |
EXHIBIT 99.1 Inventiva announces that its IND application for the Phase II combination trial with lanifibranor and empagliflozin in patients with NASH and T2D has been accepted by the FDA FDA assessment concludes that the Phase II combination trial, LEGEND, may proceed The initiation of the trial is planned for H1 2022 and the publication of topline results is expected for H2 2023 Daix (France), L |
